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Abstract
Background: In a recent case-control study, the odds of metabolic syndrome (MetSyn) among
deep vein thrombosis cases was almost twice the odds as among controls. We tested the hypothesis
that the incidence of non-cancer-related venous thromboembolism (VTE) is higher among adults
with MetSyn and further, that associations are stronger for idiopathic than secondary VTE.
Methods: 20,374 middle-aged and elderly adults were followed for over 12 years for incident VTE
in the Longitudinal Study of Thromboembolism Etiology (LITE). All hospitalizations were identified
and VTEs validated by chart review. Baseline MetSyn was defined usingATP III guidelines including
≥3 of abdominal obesity, elevated blood pressure, low HDL-cholesterol, high triglycerides, and high
glucose. Because sex modified the relation between MetSyn and VTE (pinteraction=0.001),
proportional hazards regression analyses were stratified by sex to assess the associations of MetSyn
and its components with risk of incident non-cancer related VTE, adjusting for potential confounders.
Results: Incident VTE (n=358) included 196 idiopathic events. Baseline MetSyn was associated
with risk of total VTE (Hazard Ratio (HR) 1.84; 95%CI 1.30, 2.59) and idiopathic VTE (HR 1.59,
95% CI 1.02, 2.47) among men, but not women. The association was largely attributable to abdominal
obesity (HR of VTE = 2.10, 95% CI 1.51, 2.93 in men and 1.70, 95% CI 1.24, 2.34 in women), with
no additional contribution by the other MetSyn components.
Conclusion: Although abdominal obesity was associated with increased risk of VTE in both men
and women, MetSyn and its other components do not seem important in VTE etiology.
INTRODUCTION
Several studies suggest a link between venous thromboembolism (VTE) and atherosclerosis
via common risk factors, including central adiposity (1,2), obesity (3,4), smoking (1,3),
hypertension (3), low HDL-cholesterol (5), high LDL-cholesterol (5), high levels of lipoprotein
(a) (6), and diabetes (4). However, results have been inconsistent (1,3-7). In the Longitudinal
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Investigation of Thromboembolism Etiology (LITE), obesity and type 2 diabetes were
associated with VTE, but not other traditional atherosclerosis risk factors (4). Several of these
risk factors are components of the metabolic syndrome (MetSyn), known to be associated with
atherosclerotic disease risk (8).
According to national surveys (9), about 23% of the US adult population has the MetSyn
(defined as 3 or more of the following risk factors: central adiposity, elevated systolic blood
pressure, elevated triglycerides, elevated glucose or diagnosed with diabetes, low HDL-
cholesterol). In a recent case-control study, over 50% of idiopathic deep vein thrombosis (DVT)
cases had the MetSyn compared to 35% of controls. After adjusting for age, sex, body mass
index, and smoking, the prevalence of the MetSyn was almost twice as likely in idiopathic
DVT cases as controls (OR 1.93; 95% CI: 1.05, 3.56) (10). Results from another case-control
study showed 35% of recurrent VTE patients had the MetSyn compared to 20% of controls
(OR = 2.2; 95% CI: 1.1, 4.3) (11). The mechanism by which the MetSyn could be associated
with VTE may be through endothelial dysfunction and a procoagulant state, reflected by
elevated factors such as factors VII and VIII, and vonWillebrand factor (12-15).
To date, there are no published prospective studies investigating the relation between MetSyn
and risk of incident VTE in middle-aged and elderly men and women. We tested the hypothesis
in the LITE study of VTE in the Atherosclerosis Risk in Communities (ARIC) study and the
Cardiovascular Health Study (CHS), that incidence of non-cancer related VTE is higher among
adults with the MetSyn compared to those without, independent of age, sex, race, and factor
VIIIc. In addition, we hypothesized that associations would be stronger for idiopathic than
secondary VTE.
METHODS
Study design and population
The Longitudinal Investigation of Thromboembolism Etiology (LITE) is a prospective study
of VTE occurrence in two population-based cohorts: the Atherosclerosis Risk in Communities
(ARIC) study (16) and the Cardiovascular Health Study (CHS) (17,18). ARIC examined
15,792 45- to 64-year old African American and white female and male residents recruited in
1987-89 from the city of Jackson, MS; selected suburbs of Minneapolis, MN; Forsyth County,
NC; and Washington County, MD. CHS examined 5,888 65+ year-old primarily white and
African American female and male residents recruited in 1989-90 or 1992-93 from the city of
Pittsburgh, PA; Forsyth County, NC; Sacramento County, CA; and Washington County, MD
and who were randomly selected from the Health Care Financing Administration (or Medicare)
eligibility lists.
Data Collection
The Institutional Review Boards of all participating centers approved this study. Study
participants underwent a comprehensive baseline examination for cardiovascular disease
(CVD) risk factors. In both studies, seated blood pressure was measured using a random-zero
sphygmomanometer. BMI was calculated as weight in kilograms divided by the square of
standing height in meters. Waist circumference was measured at the umbilicus. Fasting blood
specimens were collected, centrifuged at 4° C., and plasma and serum frozen at −70° C. until
analysis in central laboratories. Lipids, glucose, fibrinogen, and factors VIIc and VIIIc were
measured at baseline (19). Diabetes status (yes or no) was defined at baseline as fasting glucose
≥ 126 mg/dL, nonfasting glucose ≥ 200 mg/dL, or a history of or treatment for diabetes.
Smoking status, hormone replacement use in women, and medication use were also obtained
at baseline.
Steffen et al. Page 2













MetSyn was defined according to ATP III recommendations as 3 or more risk factors (20),
including:
• Abdominal obesity: waist circumference ≥ 102 cm for men and ≥ 88 cm for women;
• Triglycerides ≥ 150 mg/dL;
• HDL-cholesterol levels for men < 40 mg/dL and for women < 50 mg/dL.
• Glucose ≥ 100 mg/dL, on drug treatment for elevated glucose, or a diagnosis of
diabetes;
• Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or on
antihypertensive therapy;
Case ascertainment
Study participants were followed for VTE (deep vein thrombosis (DVT) or pulmonary
embolism (PE)) endpoints through 2001 in CHS and 2002 in ARIC. Hospitalizations were
identified by participant or proxy report via annual telephone calls and surveillance of
community hospitals in ARIC (16) or via alternating clinic visits and telephone contact every
6 months and by search of Health Care Financing Administration records in CHS (18). For all
hospitalizations, ICD-9-CM discharge codes were recorded and were used to identify medical
records of possible VTE event (21). Medical records were obtained and reviewed by two
physicians. VTE events were classified independently, and differences resolved through
discussion. VTE required objective evidence from imaging or autopsy. DVT was nearly always
defined as a positive duplex ultrasound or venogram, but rarely in the earliest years, by a
positive Doppler ultrasound or impedance plethysmography. PE nearly always was defined by
a ventilation-perfusion scan with multiple segmental or subsegmental mismatched defects, or
a positive pulmonary angiogram or computed tomography. Idiopathic VTE events were
defined as VTE excluding obvious precipitants (e.g. surgery, trauma, recent hospitalization,
or severe immobility) (21).
Statistical analysis
Of the 15,792 ARIC participants and 5,888 CHS participants, we excluded from the analyses
those with a history of VTE before baseline (n=477), who used warfarin at baseline (n=185),
or who developed cancer-related VTE during follow-up (n=125). We further excluded 933
individuals with non-fasting blood specimens and other missing data. Seventy-two individuals
were excluded because they were not white or African American, leaving 20,374, including
11,429 women and 8,945 men.
All analyses were conducted using the statistical software package SAS, version 9.1 (SAS
Institute; Cary, NC). Follow-up time was calculated as time from baseline to incident VTE,
death, last follow-up contact, or through 2001 for CHS and 2002 for ARIC, whichever occurred
first. Means and proportions were computed to describe baseline characteristics of participants
by metabolic syndrome status and for those who did or did not develop VTE. Hazard ratios
were calculated, adjusted for age, race, sex, and other covariates, using proportional hazards
regression models. After assessing for potential effect modification by race or sex, regression
models were stratified by sex (pinteraction=0.001). The relations for idiopathic VTE cases only
were also evaluated. In sensitivity analysis, we assessed whether adjustment for lipid
medication use changed study findings.
RESULTS
Over 56% of the LITE cohort was female and 23% African American. At baseline, study
participants were average age 58.9 (10.1) years. For women and men, the average BMI (SD)
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was 27.6 (5.9) and 27.2 (4.1) kg/m2, and 62% and 70% were overweight or obese, respectively.
Almost 34% of women and 30% of men had MetSyn at baseline. Mean levels of risk factors
were greater among individuals with MetSyn than among those without MetSyn (Table 1).
Similar findings were observed when risk factors were stratified by abdominal obesity instead
of MetSyn (data not shown).
As shown in Table 2, the prevalence of metabolic syndrome among women who did or did not
develop incident VTE was similar (both 34%), however, the prevalence of MetSyn was greater
among men who developed incident VTE than among those who did not (44% vs. 30%,
p<0.001). Abdominal obesity was significantly greater among both men and women who
developed VTE than among those who did not. Interestingly, more women who did not develop
VTE had low HDL-cholesterol than women who did develop VTE, whereas, there was no
significant difference between groups for men.
Over an average 12.5 years of follow-up, there were 358 incident non-cancer related VTE
events, including 195 idiopathic events. While most components of the MetSyn were not
significantly related to VTE, abdominal obesity was significantly and positively related to VTE
risk in both men and women (Model 1, Table 3). Compared with those free of Metsyn, MetSyn
was associated with a higher risk of incident VTE among men (HR=1.84, 95% CI 1.30-2.59),
but not women (Model 2, Table 3). HRs were smaller (1.59; 95% CI 1.02, 2.47) for the
relationship between MetSyn and idiopathic than secondary VTE in men (Model 2, Table 3).
Further adjustment for fibrinogen and factors VIIc and VIIIc in statistical models only slightly
attenuated associations (data not shown). Results were similar after excluding individuals who
were taking lipid-lowering medication (data not shown). In LITE, the major race group is
Caucasian (77%). Race was not an effect modifier or a significant confounding factor in the
statistical models. When we analyzed the data excluding African Americans, similar results
were observed for whites as when both races were included in the model. For white men only
the HR for risk of developing VTE was 2.02 (95% CI 1.38, 2.94) and for white women only,
the HR for risk of developing VTE was 0.88 (95% CI 0.62, 1.25).
To determine if abdominal obesity was the sole predictor of VTE rather than the cluster of
MetSyn components, a model was run that included abdominal obesity, a variable representing
the cluster of MetSyn components but without abdominal obesity, and the previously identified
confounding factors (Model 3, Table 3). Abdominal obesity was associated with incident VTE
in men (HR 2.10 95% CI 1.51, 2.93) and women (HR 1.70, 95% CI 1.24, 2.34), but not ‘MetSyn
without abdominal obesity’ in men (HR 1.28, 95% CI 0.92, 1.79) or women (HR 0.84, 95%
CI 0.63, 1.12). The HRs relative to abdominal obesity or ‘MetSyn without abdominal obesity’
were similar for idiopathic VTE and for total VTE.
DISCUSSION
Over 12 years of follow-up, MetSyn was associated with 84% increased risk of developing
non-cancer related VTE among men, but not women. Moreover, the cluster of the MetSyn
components minus abdominal obesity was not related to VTE risk, so that only abdominal
obesity, but not MetSyn, per se was associated with increased risk of VTE. Results were similar
for idiopathic VTE events.
Some investigators suggest a link between VTE and atherosclerosis through common risk
factors (2,7), including obesity and abdominal obesity, diabetes, HDL-cholesterol, high blood
pressure, smoking (1-3,5,6,22), and most recently MetSyn (10,11); however, study findings
have not consistently shown that these factors are risk factors for VTE (4,7,22). Two case-
control studies demonstrated higher prevalence of the MetSyn in idiopathic DVT or recurrent
VTE patients than controls (10,11). However, in our prospective study of over 20,000 male
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and female participants, abdominal obesity was the only component of MetSyn related to
incident VTE, and not the cluster of other components of the MetSyn.
Even though diabetes, a known risk factor for VTE (4,7,22), is accompanied by increased
coagulation factors (23) and increased platelet reactivity (24), elevated glucose levels were not
related to VTE risk in our study. The evidence is less consistent for hypertension associating
with VTE (3,4,7), and elevated blood pressure (defined as SBP≥130 mmHg or DBP≥85 mmHg)
was not related to incident VTE in the current study or others (22).
Low HDL-cholesterol is a strong risk factor for atherosclerotic events, however, it was related
to VTE in only one case-control study (5), but not in prospective studies (4). In the current
study, low HDL-cholesterol (<40 mg/dL in men and <50 mg/dL in women) was not
significantly related to incident VTE. Furthermore, the prevalence of low HDL-cholesterol
was higher among women who did not develop VTE than those who did develop incident VTE.
High triglyceride concentrations (≥ 150 mg/dL), another component of the MetSyn, also was
not related to VTE in LITE.
Our results are consistent with those in other studies of abdominal obesity. In men born in
1913, waist circumference greater than 100 cm was associated with a three-fold increased risk
of VTE compared to a waist size less than 100 cm (1). One meta-analysis, including 4 case-
control studies and the LITE study, evaluated the effect of obesity (BMI>30 kg/m2) on VTE
and reported an increased odds ratio of 1.84 (95% CI 1.55, 2.18) (22). In the current analysis,
abdominal obesity doubled the risk of developing VTE in both men and women; whereas,
MetSyn was related to VTE in men only. Analogously, previous studies have sometimes found
gender-specific differences in the association between MetSyn and arterial disease (25).
It is biologically plausible that risk of VTE in abdominally obese individuals is mediated by a
state of hypercoagulability and endothelial cell injury, two of three components of Virchow's
triad involved in the pathogenesis of VTE (7,22-24,26,27). Several studies have demonstrated
elevated hemostatic factors in abdominal obesity, including factor VII, fibrinogen, von
Willebrand factor (vWF), and PAI-1 (14,27-30), and these markers are sometimes elevated in
VTE, especially vWF (13,31,32). In the current study, individuals with MetSyn and abdominal
obesity had higher levels of fibrinogen and factors VIIc and VIIIc than those without MetSyn
or abdominal obesity.
A major strength of this investigation is the prospective study design examining the relation
between MetSyn and VTE. The study followed a large number of primarily white and African
American middle-aged and elderly men and women over 12 years. We measured and adjusted
for several VTE risk factors but it is possible there was residual confounding by unaccounted
for factors associated with both MetSyn and VTE. A limitation of the study is that MetSyn was
defined several years before the VTE event, therefore, if there were acute effects of MetSyn
they could have been missed.
MetSyn is associated with chronic disease, including coronary heart disease (8,12,20,30), and
type 2 diabetes (8,12,20), but not with incident VTE in this prospective study. Abdominal
obesity, an established VTE risk factor was important, but not the cluster of other MetSyn
components.
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Table 1






BMI, kg/m2 30.7 (0.08) 26.0 (0.06)
Waist circumference, cm 104 (0.22) 90 (0.15)
Glucose, mg/dL‡ 118 96
HDL-cholesterol, mg/dL 47 (0.24) 64 (0.17)
Triglycerides, mg/dL‡ 162 93
Systolic blood pressure, mmHg 131 (0.30) 122 (0.21)
Diastolic blood pressure, mmHg 74 (0.17) 70 (0.12)
Fibrinogen, mg/dL 325 (1.17) 308 (0.69)
Factor VIIc, % 135 (0.49) 123 (0.35)






BMI, kg/m2 29.9 (0.07) 26.0 (0.05)
Waist circumference, cm 106 (0.2) 95 (0.1)
Glucose, mg/dL‡ 121 101
HDL-cholesterol, mg/dL 37 (0.24) 49 (0.2)
Triglycerides, mg/dL‡ 183 103
Systolic blood pressure, mmHg 131 (0.3) 123 (0.2)
Diastolic blood pressure, mmHg 78 (0.2) 74 (0.1)
Fibrinogen, mg/dL 312 (1.2) 300 (0.8)
Factor VIIc, % 119 (0.5) 109 (0.3)
Factor VIIIc, % 130 (0.7) 123 (0.5)
*
Adjusted for age, race, field center, education, smoking, and hormone replacement therapy (women)
†
All means are significantly different between metabolic syndrome categories, p<0.001
‡
Geometric means
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Table 2
Frequency of metabolic syndrome components among study participants who did or did not develop venous
thromboembolism (VTE), LITE Study
Characteristic Women (n=11,429)*
Metabolic Syndrome Components Developed VTE (n=210) Did not develop VTE
(n=11,226)
 Abdominal obesity, n (%) 152 (72%) 6854 (61%) †
 High glucose, n (%) 45 (19%) 2347 (21%)
 Low HDL-cholesterol, n (%) 58 (29%) 3924 (35%) †
 High triglycerides, n (%) 50 (22%) 2847 (25%)
 Elevated blood pressure, n (%) 136 (57%) 5810 (52%)
MetSyn, n (%) 71 (34%) 3788 (34%)
Men (n=8,945)*
Metabolic Syndrome Components Developed VTE (n=149) Did not develop VTE (n=8798)
 Abdominal obesity, n (%) 75 (51%) 2833 (32%) ‡
 High glucose, n (%) 65 (47%) 2387 (40%) †
 Low HDL-cholesterol, n (%) 50 (35%) 3491 (32%)
 High triglycerides, n (%) 96 (57%) 2791 (52%)
 Elevated blood pressure, n (%) 55 (36%) 4562 (27%)
MetSyn, n (%) 65 (44%) 2619 (30%) ‡
MetSyn = metabolic syndrome defined according to the ATP III guidelines
MetSyn w/o abdominal obesity = metabolic syndrome defined as 2 or more components excluding abdominal obesity
*
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Table 3
Hazard ratios (95% confidence intervals) of non-cancer related venous thromboembolism in relation to metabolic
syndrome and its components, LITE study












VTE case, n 209 149 113 82
Model 1*
MetSyn Components
 Abdominal Obesity 1.75 (1.27, 2.41) 2.14 (1.49, 2.93) 1.91 (1.23, 2.95) 2.42 (1.53, 3.81)
 High glucose 0.94 (0.66, 1.33) 1.26 (0.89, 1.79) 0.92 (0.57, 1.49) 1.06 (0.65, 1.72)
 High triglycerides 0.81 (0.57, 1.15) 0.88 (0.61, 1.27) 0.80 (0.49, 1.29) 0.79 (0.48, 1.32)
 Low HDL-cholesterol 0.80 (0.59, 1.09) 1.29 (0.90, 1.84) 0.59 (0.37, 1.04) 1.57 (0.98, 2.52)
 Elevated blood pressure 1.30 (0.95, 1.78) 1.17 (0.82, 1.68) 1.29 (0.85, 1.98) 0.83 (0.52, 1.33)
Model 2†




0.84 (0.63, 1.12) 1.28 (0.92, 1.79) 0.76 (0.51, 1.13) 1.19 (0.76, 1.87)
 Abdominal obesity 1.70 (1.24, 2.34) 2.10 (1.51, 2.93) 1.84 (1.19, 2.84) 2.31 (1.48, 3.62)
MetSyn = metabolic syndrome
*
Model 1 includes all metabolic syndrome components adjusted for age, race, field center, education, smoking, and hormone replacement therapy
(women)
†
Model 2 includes the indicator variable metabolic syndrome (yes/no) adjusted for age, race, field center, education, smoking, and hormone
replacement therapy (women)
‡
Model 3 includes 2 indicator variables: abdominal obesity (yes/no) and the metabolic syndrome components without abdominal obesity (yes/no)
adjusted for age, race, field center, education, and smoking
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